Indo US Bio-Tech Sales and Profits Analyzed

Indo US Bio-Tech had a tough quarter. Sales went down by 3.23%, dropping to 22.80 crore rupees. This is a significant change from the previous quarter where sales were 23.56 crore rupees.

Key Points

• Sales decreased 3.23%, reaching 22.80 crore rupees.
• Net profit fell sharply, down 40.59% to 3.00 crore.
• Previous quarter profit was 5.05 crore rupees.
• Operating profit margin (OPM) decreased to 18.20%.
• Profit Before Tax (PBDT) reduced by 34% to 3.39 crore.
• Net Profit (NP) decreased by 41% to 3.00 crore.

Financial Performance Breakdown

The company’s profit also took a major hit. Net profit fell by a huge 40.59% – going from 5.05 crore rupees to just 3.00 crore rupees. This means the company isn’t making as much money as it was before.

Looking at the numbers closer, the company’s profit before tax (PBDT) also decreased by 34%, dropping from 5.17 crore rupees to 3.17 crore rupees. This reduction directly impacts the final net profit.

Margins and Key Metrics

Operating Profit Margin (OPM) provides a glimpse into efficiency. It decreased from 23.47% to 18.20%, suggesting the company’s operations are becoming less profitable.

The decrease in both PBDT and NP highlights the challenges Indo US Bio-Tech is facing. These figures reflect a need for strategic adjustments to improve overall financial performance.

Ultimately, the company’s financial results indicate a critical need for immediate action and strategic realignment.